Medpace Holdings
Open
$420.83
Prev. Close
$420.83
High
$421.02
Low
$420.71
Market Snapshot
$11.74B
25.5
13.06
$2.11B
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 5,900 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Medpace Holdings faces a class action lawsuit after a 15.9% stock drop due to allegations of misleading investors about its book-to-bill ratio and backlog risks.
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 5,900 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Recently from Cashu
Medpace Holdings Leadership Strengthens Commitment with Major Stock Purchase Amid Growth Prospects
Medpace Holdings Sees Strengthened Leadership Commitment Amid Robust Growth Prospects Medpace Holdings, a key player in the biopharmaceutical sector, recently demonstrates a strong commitment to its f…
Medpace Holdings Faces Scrutiny After CEO's Insider Sale and Its Impact on Clinical Research
Medpace Holdings: Executive Actions and Their Implications for Clinical Research Medpace Holdings, a prominent player in the clinical research industry, is currently facing scrutiny following an insid…
Medpace Holdings: CEO's Insider Sale Raises Questions About Future and Investor Confidence
Medpace Holdings' Executive Actions Spark Investor Curiosity Medpace Holdings, a key player in the clinical research landscape, recently garners attention following CEO August J. Troendle's insider sa…
Medpace Holdings: Growth Continues Despite Executive Insider Share Sale
Medpace Holdings: Continued Growth Amid Executive Insider Sale Medpace Holdings, a leading clinical contract research organization (CRO), experiences significant executive movement as CEO August J. Tr…